)

Aldeyra Therapeutics (ALDX) investor relations material
Aldeyra Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Lead candidate and regulatory milestones
Reproxalap's PDUFA date is set for December 16, with a potential $194 million option exercise by AbbVie within 10 business days post-approval.
NDA resubmission addressed prior FDA concerns about baseline imbalances; new trial showed only a two-point difference between arms.
Accepted NDA includes phase 3 dry eye chamber trial data, supporting rapid onset of efficacy for ocular discomfort and redness.
Over 2,000 patients have been treated with reproxalap, with no known safety issues reported in the field trial safety update.
AbbVie remains highly engaged, with expanded commercial supply rights and ongoing pre-commercial and development activities.
Product differentiation and market opportunity
Reproxalap is positioned as the only chronic dry eye drug with redness data on the label, addressing both signs and symptoms rapidly.
The drug's RASP modulation mechanism targets multiple inflammatory pathways, potentially improving both redness and discomfort.
Market opportunity is significant due to increasing dry eye prevalence from behavioral and environmental factors.
Current treatments require weeks or months for efficacy; reproxalap aims to provide relief in minutes, especially for flare-ups.
No other dry eye drug has dry eye chamber flare data in its label, offering a unique commercial advantage.
Pipeline progress and future catalysts
ADX-2191, an intravitreal methotrexate, is in a pivotal trial for ocular lymphoma, with data expected by end of next year.
ADX-2191 also holds Fast Track and EMA orphan designations for retinitis pigmentosa and primary vitreoretinal lymphoma.
RASP pipeline includes ADX-248 (oral for atopic dermatitis, phase 1 ongoing) and ADX-246 (injectable for dry age-related macular degeneration, phase 1 planned).
ADX-248 aims to be the first oral drug for mild to moderate atopic dermatitis, addressing a large unmet need, especially in pediatrics.
Multiple late-stage and early-stage catalysts are anticipated through 2025 and 2026, ensuring regular news flow.
Next Aldeyra Therapeutics earnings date

Next Aldeyra Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage